Hi Primaus72
Just to confirm the 6 week data is the same data and therefore same patients from the 2 phase 3 trials. It is just the first check point from the 2 trials data set.
You will see the chart in the investor presentation they did in June.
PXS just need to prove that the data first taken at 6 weeks is a reliable indication of how you respond over the next 6 months. If they can do that then it removes all arguments in so far as
1) You agree with the EMEA what the improvement needs to be at 6 weeks to stay on the drug. This can be FEV1 of any % or a mixture of FEV1 and reduced infections.
2) It removes all age variabilty as only those who respond to point 1 above stay on the drug.
3) Safety issues are reduced because again non responders drop out after 6 weeks treatment so the benefit of those who stay on the drug outweighs what appears really to be non safety issues.
Cheers
- Forums
- ASX - By Stock
- update
Hi Primaus72Just to confirm the 6 week data is the same data and...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SNT (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.3¢ |
Change
0.004(10.3%) |
Mkt cap ! $59.04M |
Open | High | Low | Value | Volume |
4.0¢ | 4.3¢ | 4.0¢ | $127.5K | 3.135M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 107401 | 4.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.3¢ | 73324 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 107401 | 0.042 |
2 | 450008 | 0.041 |
6 | 1083186 | 0.040 |
5 | 1150900 | 0.039 |
3 | 1031600 | 0.038 |
Price($) | Vol. | No. |
---|---|---|
0.043 | 73324 | 3 |
0.044 | 408500 | 3 |
0.045 | 51900 | 3 |
0.046 | 130236 | 2 |
0.047 | 184764 | 1 |
Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |